Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:52 2024-04-29 am EDT			5-day change	1st Jan Change
0.474 ^SEK	-0.11%		-3.27%	-9.37%

Apr. 16	Mendus AB Announces Board Changes	CI
Mar. 27	Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	CI

Mendus to participate in upcoming industry conferences

April 08, 2024 at 02:00 am EDT

Press release
Stockholm, Sweden, January 8, 2024

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences:

Executive Insights 2024
Stockholm, Sweden, April 9, 2024
CEO Erik Manting will participate in the annual Executive Insights Forum: Drugs and Money in a Time of Change. Executive Insights is a networking event for Swedish executives and investors.
https://executive-insights-2024.confetti.events/

Investing in Oncology Forum
Stockholm, Sweden, April 10, 2024
CEO Erik Manting will present and take part in a panel discussion at the Investing in Oncology Forum 2024 hosted by Cord Communications.
https://financialhearings.com/event/49788

EBMT 2024
Glasgow, Scotland, April 14-17, 2024
CMO Jeroen Rovers will participate in the 50th annual meeting of EBMT, a non-profit medical and scientific organization connecting patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies.
https://www.ebmt.org/annual-meeting-2024

Van Lanschot Kempen Life Sciences Conference
Amsterdam, The Netherlands, April 16-17, 2024
Mendus management will participate in the annual Van Lanschot Kempen Life Sciences investor conference.
https://www.vanlanschotkempen.com/en-nl/investment-banking/equities/life-sciences-and-healthcare/life-sciences-conference-2024

LSX World Congress 2024
London, April 29-30, 2024
CEO Erik Manting will present and take part in a discussion panel at the 10th annual LSX World Congress which will take place in London.
https://informaconnect.com/lsx-world-congress/biotech-leaders/

For more information, please contact:
Erik Manting, CEO
E-mail: ir@mendus.com

About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/

Latest news about Mendus AB

Mendus AB Announces Board Changes	Apr. 16	CI
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	Mar. 27	CI
Transcript : Mendus AB - Special Call	Mar. 12
Transcript : Mendus AB, 2023 Earnings Call, Feb 14, 2024	Feb. 14
Mendus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Certain Ordinary Shares of Mendus AB are subject to a Lock-Up Agreement Ending on 27-JAN-2024.	Jan. 26	CI
Mendus AB Announces Clinical Pipeline Update	Dec. 22	CI
Transcript : Mendus AB - Special Call	Dec. 14
Mendus AB Appoints Ted Fjällman as Board Member	Dec. 13	CI
Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023	Dec. 11	CI
Mendus AB and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML	Dec. 06	CI
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting	Nov. 17	CI
Transcript : Mendus AB, Nine Months 2023 Earnings Call, Nov 09, 2023	Nov. 09
Mendus AB Presents Updated Alison Clinical Trial Data for Vididencel in Ovarian Cancer At SITC 2023	Nov. 06	CI
Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal	Nov. 03	CI
Mendus AB Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data	Nov. 02	CI
Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23	23-09-21	CI
Mendus Obtains US FDA's Fast Track Tag for Blood Cancer Therapy	23-09-08	MT
Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia	23-09-08	CI
Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Mendus AB Announces the Publication of Novel Preclinical Data on its Intratumoral Priming Strategy in the Peer-Reviewed Medical Journal 'Frontiers in Immunology	23-08-16	CI
Mendus AB announced that it has received funding from Flerie Invest AB	23-07-30	CI
Transcript : Mendus AB - Special Call	23-06-27
Mendus AB Appoints Lewis Lanier to Scientific Advisory Board	23-06-20	CI
Sweden’s Mendus Receives European Medicines Agency Certification for Cancer Vaccine	23-06-19	MT

Chart Mendus AB

Duration

Period

More charts

Company Profile

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Sector

Biotechnology & Medical Research

Calendar

2024-05-16 - Annual General Meeting

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MENDUS AB	-9.37%	43.68M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research

Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Mendus to participate in upcoming industry conferences

Latest news about Mendus AB

Chart Mendus AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research